scholarly journals Wind-Wave Interaction in Sengguruh Reservoir and The Effect to Riprap Material

2021 ◽  
Vol 930 (1) ◽  
pp. 012070
Author(s):  
J Fidari
Keyword(s):  
Side Effects ◽  
High Risk ◽  
Wind Wave ◽  
Wave Interaction ◽  
Dam Safety ◽  
Coastal Structures ◽  
Safety Standards ◽  
Water Interaction ◽  
Large Dams ◽  
Public Company

Abstract The Sengguruh Dam is one of the large dams managed by Jasa Tirta I Public Company. This reservoir has been operating for more than 38 years (operating since 1982 and the latest data is for 2020). This research was conducted to determine the effect of wind and the interaction of wind on the water in the Sengguruh Dam. Most of the interaction of water and wind is mostly carried out on coastal structures but rarely investigated in the upstream area of the river basin. Investigations were carried out to obtain an overview and characteristics of the influence of the two variables of wind and water on the hydraulics of the reservoir storage, sedimentation in the water column, and side effects of the embankment material in the riprap dam. This study will provide an overview of the condition of the Sengguruh Dam which is full of sediment and shows the wind and water interaction that occurs in the reservoir as well as the potential hazards that are quite large for the management of water resources and disasters in the surrounding community if there is a high risk or threat that occurs if these conditions do not meet dam safety standards in Indonesia.

scholarly journals Simulation-based study of wind-wave interaction

2018 ◽  
Vol 26 ◽  
pp. 162-173 ◽  
Author(s):  
Xuanting Hao ◽  
Tao Cao ◽  
Zixuan Yang ◽  
Tianyi Li ◽  
Lian Shen
Keyword(s):  
Wind Wave ◽  
Wave Interaction ◽  
Simulation Based

scholarly journals A risk scoring system for seafood supply chain breaches and examination of freshwater fish imported to Australia

2021 ◽  
Vol 5 ◽  
Author(s):  
Michelle Williams ◽  
Marta Hernandez-Jover ◽  
Thomas Williams ◽  
Shokoofeh Shamsi
Keyword(s):  
Supply Chain ◽  
High Risk ◽  
Freshwater Fish ◽  
Scoring System ◽  
Outcome Variable ◽  
Scoring Method ◽  
Safety Standards ◽  
The Third ◽  
Risk Scoring ◽  
Legislative Changes

Abstract Legislative changes have altered the way imported edible seafood is inspected in Australia. Greater onus of responsibility has been placed on exporting countries to provide documentary evidence of adherence to internally recognized food safety standards. According to global trade agreements, any additional safety tests applied to freshwater fish imported into Australia must be justified. Therefore, the aim of this study was to develop a risk scoring method to provide justification for identifying countries as ‘Freshwater fish high risk’ and to examine the seafood they export to Australia for seafood supply chain breaches. Scoring was conducted using six predictor variables, identified in the literature as important contributors to seafood supply chain breaches, to achieve the outcome variable, Country considered ‘Freshwater fish high risk’. Sixty-seven fish fillets (9.55 kg) of the same species were examined from the third highest scoring country (Country 20) and 562 (5.6 kg) whole fish from the sixth highest scoring country (Country 22). Country 20 had supply chain breaches of 28 macroscopic yellow cysts in one fillet. Two hundred and thirteen parasites and other supply chain breaches were identified in fish from Country 22, including retained liver (91 per cent), visible mud (11 per cent), a variety of debris (16 per cent) and, depending on the commodity code, these fish were imported to Australia under full intestine (90 per cent), retained gills (89 per cent), and partial intestine (9 per cent). Three serious physical hazards were recovered from the edible portion of three ‘consumer-ready’ fish and snails of Genus Lymnaea and Indoplanorbis were recovered from gill mud also from ‘consumer-ready’ fish. The study showed variable results from the scoring system and vast differences in seafood supply chain breaches between the third and sixth highest scoring countries.

scholarly journals PEMILIHAN KONTRASEPSI BERDASARKAN EFEK SAMPING PADA DUA KELOMPOK USIA REPRODUKSI

2017 ◽  
Vol 6 (3) ◽  
pp. 167
Author(s):  
Erna Setiawati ◽  
Oktia Woro Kasmini Handayani ◽  
Asih Kuswardinah
Keyword(s):  
Side Effects ◽  
High Risk ◽  
Random Sampling ◽  
High Risk Pregnancy ◽  
Reproductive Age ◽  
Cross Sectional ◽  
Whitney Test ◽  
Mann Whitney Test ◽  
Risk Pregnancy

ABSTRACT Kelompok usia reproduksi terbagi dalam tiga fase yaitufase menunda kehamilan (<20 tahun), fase menjarangkan kehamilan (20-30 tahun) dan fase mengakhiri kehamilan (>30 tahun). Cara yang ditempuh yaitu dengan pemakaian kontrasepsi.baik  MKJPmaupunnon MKJP. Tujuan penelitian ini adalah untuk mengetahui ada atau tidak perbedaan pemilihan kontrasepsi MKJP dan non MKJP berdasarkan efek samping pada dua kelompok usia reproduksi. Penelitin ini menggunakan desain cross sectional, pengambilan data dengan kuesioner. Sampel dalam penelitian ini adalah akseptor KB baik MKJP maupun non MKJP pada bulan april sampai juni sebanyak 200 responden, dimana tekhnik pengambilan datanya dengan random sampling dan kuota sampling. Hasil penelitian kemudian diuji dengan mann-whitney test.Hasil penelitian dengan uji mann whitney test diperoleh p = 0.662 dengan kata lain p > α (0.05) yang berarti tidak ada perbedaan pemilihan MKJP dan non MKJP berdasarkan efek samping di Wilayah Kabupaten Semarang.      ABSTRACT Reproductive-age category can be divided into three groups which are the group of delayed interval pregnancy (less than 20 years old), the group of intervalcontrol pregnancy (20 to 30 years old), and the group of high risk pregnancy (more than 30 years old). An alternative to avoid high risk pregnancy is by using contraception tool namely long-term contraception (MKJP) and non long-term contraception (non MKJP).The purpose of this research is to analysedwhether there are differences in choosing MKJP and non –MKJP based on side effects in the two reproductive-age groups.This research was an explanatory research with cross-sectional design. The population were all women of contraception acceptors in Semarang Regency.The samples were 200 respondents, used simple random sampling and quota sampling. This research used quisionaire instrument and analyze used mann whitney test (α=0,05). Theresult showed thatP = 0,662 meaning P > α = 0.05 which means there is no difference in choosing MKJP and non-MKJP based on side effects in the two reproduction-age groups in Semarang regency.

Magnesium Sulphate for Seizure Prophylaxis in Women With Preeclampsia

2021 ◽  
pp. 1-6
Author(s):  
Peter Lindner ◽  
Shad Deering
Keyword(s):  
Side Effects ◽  
High Risk ◽  
Randomized Trial ◽  
Magnesium Sulphate ◽  
Neonatal Death ◽  
Maternal Morbidity ◽  
Controlled Trial ◽  
Before And After ◽  
Secondary Outcomes ◽  
High Risk Cohort

The article “Do Women With Pre-Eclampsia, and Their Babies, Benefit From Magnesium Sulphate? The Magpie Trial: A Randomized Placebo-Controlled Trial” is the first randomized trial that objectively evaluates the utility of magnesium sulphate therapy as prophylaxis against progression to eclamptic convulsions in a high-risk cohort of women. It specifically evaluates the effect of magnesium sulphate given before and after delivery on maternal progression to eclampsia and fetal/neonatal death. It also evaluates secondary outcomes such as maternal morbidity; magnesium toxicity; side effects of magnesium sulphate; and, for those who received magnesium sulphate prior to delivery, it evaluated complications of the labor process.

6081Efficacy and limitations of quinidine therapy in patients with Brugada Syndrome

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A Mazzanti ◽  
E Tenuta ◽  
M Marino ◽  
E Pagan ◽  
M Morini ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Side Effects ◽  
High Risk ◽  
Brugada Syndrome ◽  
Low Dose ◽  
Clinical Course ◽  
High Risk Group ◽  
High Dose ◽  
Life Threatening ◽  
Patients Experience

Abstract Background Quinidine at high-dose is used in patients with Brugada Syndrome (BrS), but its efficacy to prevent life-threatening arrhythmic events (LAE) in BrS is unproven and its use is limited by side effects. Objective We assessed whether low-dose quinidine in BrS patients reduces: 1) the occurrence of a first LAE; 2) the arrhythmic burden in the high-risk group of cardiac arrest survivors. Methods We first compared the clinical course of 53 BrS patients treated with quinidine to that of 441 untreated controls, matched by sex, age, and symptoms. Furthermore, we calculated the annual incidence of LAEs off- and on-quinidine in 123 BrS patients who had survived a cardiac arrest. Results First, we compared the clinical course of 53 BrS patients treated with quinidine (i.e. “cases”: 89% males, median age 40 years) to that of 441 untreated, clinically-matched BrS patients (i.e. “controls”: 91% males, median age 41 years) present in our database of patients with inherited arrhythmias. Cases received quinidine (median dose of 450 mg per day) for 5.0±3.7 years. Quinidine was interrupted in only 3/53 cases (6%) for side effects and it conferred a nonsignificant reduction of the risk of a first LAE in cases versus controls (HR 0.74, 95% CI 0.22–2.48, P=0.62). Secondly, we calculated the annual recurrence of LAE off- and on-quinidine in 123 BrS cardiac arrest survivors, 27 of whom were treated with quinidine for 7.0±3.5 years. The annual rate of recurrent LAEs decreased significantly from 14.7% while off-quinidine to 3.9% while on-quinidine (P=0.03). Notably, recurrent life-threatening arrhythmic events were recorded in 4/27 (15%) symptomatic patients while on-quinidine. Conclusion We demonstrated for the first time in the long-term that low-dose quinidine reduces the recurrence of life-threatening arrhythmias in symptomatic BrS patients, with few side effects. Remarkably, about one-fifth of symptomatic patients experience life-threatening arrhythmias while on-treatment, suggesting that quinidine cannot replace implantable defibrillators in high-risk subjects.

Syndrome of Inappropriate Antidiuretic Hormone Associated with Escitalopram Therapy

CNS Spectrums ◽  
2006 ◽  
Vol 11 (6) ◽  
pp. 429-432 ◽  
Author(s):  
Anjali Nirmalani ◽  
Saundra L. Stock ◽  
Glenn Catalano
Keyword(s):  
United States ◽  
Side Effects ◽  
High Risk ◽  
Antidiuretic Hormone ◽  
Side Effect ◽  
Parent Compound ◽  
The United States ◽  
Side Effect Profile ◽  
Significant Side Effect ◽  
Risk Patients

ABSTRACTEscitalopram is the selective serotonin reuptake inhibitor (SSRI) most recently approved for use in the United States. It is structurally related to citalopram, but is felt to have a more tolerable side-effect profile than its parent compound. Side effects are not generally serious and include headache, diarrhea, and nausea. While hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) have been associated with treatment with other SSRIs, there has only been one case of escitalopram-induced SIADH reported in the literature to date. We now report another case of a patient who developed SIADH after being treated with escitalopram for 4 weeks. The patient's hyponatremia improved following the discontinuation of escitalopram. Clinicians should be aware of this uncommon but significant side effect of SSRIs and monitor high-risk patients for the development of SIADH.

scholarly journals Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer

2011 ◽  
Vol 96 (10) ◽  
pp. 3217-3225 ◽  
Author(s):  
Joanna Klubo-Gwiezdzinska ◽  
Douglas Van Nostrand ◽  
Frank Atkins ◽  
Kenneth Burman ◽  
Jacqueline Jonklaas ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
High Risk ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Differentiated Thyroid Cancer ◽  
Progression Free Survival ◽  
Response To Treatment ◽  
High Risk Patients ◽  
Risk Patients

Abstract Background: The optimal management of high-risk patients with differentiated thyroid cancer (DTC) consists of thyroidectomy followed by radioiodine (131I) therapy. The prescribed activity of 131I can be determined using two approaches: 1) empiric prescribed activity of 131I (E-Rx); and 2) dosimetry-based prescribed activity of 131I (D-Rx). Aim: The aim of the study was to compare the relative treatment efficacy and side effects of D-Rx vs. E-Rx. Methods: A retrospective analysis was performed of patients with distant metastases and/or locoregionally advanced radioiodine-avid DTC who were treated with either D-Rx or E-Rx. Response to treatment was based on RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Results: The study group consisted of 87 patients followed for 51 ± 35 months, of whom 43 were treated with D-Rx and 44 with E-Rx. Multivariate analysis, controlling for age, gender, and status of metastases revealed that the D-Rx group tended to be 70% less likely to progress (odds ratio, 0.29; 95% confidence interval, 0.087–1.02; P = 0.052) and more likely to obtain complete response (CR) compared to the E-Rx group (odds ratio, 8.2; 95% confidence interval, 1.2–53.5; P = 0.029). There was an association in the D-Rx group between the observed CR and percentage of maximum tolerable activity given as a first treatment of 131I (P = 0.030). The advantage of D-Rx was specifically apparent in the locoregionally advanced group because CR was significantly higher in D-Rx vs. E-Rx in this group of patients (35.7 vs. 3.3%; P = 0.009). The rates of partial response, stable disease, and progression-free survival, as well as the frequency of side effects, were not significantly different between the two groups. Conclusion: Higher efficacy of D-Rx with a similar safety profile compared to E-Rx supports the rationale for employing individually prescribed activity in high-risk patients with DTC.

Sign in / Sign up

Export Citation Format

Share Document